Protein Kinases as Tumor Biomarkers and Therapeutic Targets.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Current pharmaceutical design

• Publication date

  2017-07-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/1381612823666170720113216PMID 28730960
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview

  2017cited by this paper
• Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib

  2017cited by this paper
• HER3 as a Therapeutic Target in Cancer

  2017cited by this paper
• A mini-review of c-Met as a potential therapeutic target in melanoma.

  2017cited by this paper
• JAK family members: Molecular cloning, expression profiles and their roles in leptin influencing lipid metabolism in Synechogobius hasta.

  2017cited by this paper
• Src-family tyrosine kinases and the Ca2+ signal.

  2017cited by this paper
• Risk of Hypertension With Sorafenib Use in Patients With Cancer: A Meta-Analysis From 20,494 Patients

  2017cited by this paper
• Paclitaxel: What has been done and the challenges remain ahead.

  2017cited by this paper
• Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials

  2017cited by this paper
• TGF‐β Signaling in Cancer

  2016cited by this paper
• Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.

  2016cited by this paper
• Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer.

  2016cited by this paper
• The breadth of biomarkers and their assays.

  2016cited by this paper
• Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations

  2016cited by this paper
• Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs

  2016cited by this paper
• Erlotinib-related keratopathy in a patient underwent laser in situ keratomileusis

  2016cited by this paper
• Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo

  2016cited by this paper
• Genomic landscape of gastric cancer: molecular classification and potential targets

  2016cited by this paper
• Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?

  2016cited by this paper
• JAK-STAT signaling in cancer: From cytokines to non-coding genome.

  2016cited by this paper
• Phosphorylation of TOPK at Y74, Y272 by Src increases the stability of TOPK and promotes tumorigenesis of colon

  2016cited by this paper
• PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer

  2016cited by this paper
• Platelet‐derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape

  2015cited by this paper
• Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.

  2015cited by this paper
• Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer.

  2015cited by this paper
• A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.

  2015cited by this paper
• “OMIC” tumor markers for breast cancer: A review

  2015cited by this paper
• Imatinib‐induced agranulocytosis in patients with gastrointestinal stromal tumors

  2015cited by this paper
• The history and future of targeting cyclin-dependent kinases in cancer therapy

  2015cited by this paper
• The JAK-STAT pathway: impact on human disease and therapeutic intervention.

  2015cited by this paper
• Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.

  2015cited by this paper
• A historical overview of protein kinases and their targeted small molecule inhibitors.

  2015cited by this paper
• Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M

  2015cited by this paper
• Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in gastric cancer

  2015cited by this paper
• Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.

  2015cited by this paper
• Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia

  2014cited by this paper
• Getting Syk: spleen tyrosine kinase as a therapeutic target.

  2014cited by this paper
• Maternal Embryonic Leucine Zipper Kinase: Key Kinase for Stem Cell Phenotype in Glioma and Other Cancers

  2014cited by this paper
• Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer

  2014cited by this paper
• Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

  2014cited by this paper
• Prognostic and predictive biomarkers in lung cancer. A review

  2014cited by this paper
• HER2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer.

  2014cited by this paper
• Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma

  2014cited by this paper
• Epidermal growth factor receptor mutations in lung adenocarcinoma

  2014cited by this paper
• All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study.

  2014cited by this paper
• Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic

  2014cited by this paper
• The BRAF mutation is associated with the prognosis in colorectal cancer

  2014cited by this paper
• Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.

  2014cited by this paper
• Improved survival with bevacizumab in advanced cervical cancer.

  2014cited by this paper
• Expression of PDZ-binding kinase/T-LAK cell-originated protein kinase (PBK/TOPK) in human urinary bladder transitional cell carcinoma.

  2014cited by this paper
• The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells

  2014cited by this paper
• Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)

  2014cited by this paper
• Updated UK Recommendations for HER2 assessment in breast cancer

  2014cited by this paper
• AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

  2014cited by this paper
• The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.

  2014cited by this paper
• Highlights of the Latest Advances in Research on CDK Inhibitors

  2014cited by this paper
• EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer

  2014cited by this paper
• Network-based approach identified cell cycle genes as predictor of overall survival in lung adenocarcinoma patients.

  2013cited by this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2013cited by this paper
• Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

  2013cited by this paper
• The long journey of cancer biomarkers from the bench to the clinic.

  2013cited by this paper
• Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma

  2013cited by this paper
• TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma.

  2013cited by this paper
• Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck.

  2013cited by this paper
• Targeting the PDGF signaling pathway in tumor treatment

  2013cited by this paper
• Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer.

  2013cited by this paper
• Stem cell factor receptor/c-Kit: from basic science to clinical implications.

  2012cited by this paper
• HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.

  2012cited by this paper
• mTOR signaling in growth control and disease.

  2012cited by this paper
• Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

  2012cited by this paper
• Targeting MET in cancer: rationale and progress

  2012cited by this paper
• PIM1 kinase as a target for cancer therapy

  2012cited by this paper
• Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.

  2012cited by this paper
• Overexpression of T‐LAK cell‐originated protein kinase predicts poor prognosis in patients with stage I lung adenocarcinoma

  2012cited by this paper
• BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy

  2012cited by this paper
• Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis

  2012cited by this paper
• The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer

  2012cited by this paper
• Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma

  2012cited by this paper
• Balancing repair and tolerance of DNA damage caused by alkylating agents

  2012cited by this paper
• Epithelial-mesenchymal transitions: insights from development

  2012cited by this paper
• TGFβ signalling in context

  2012cited by this paper
• The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer.

  2011cited by this paper
• The CDK inhibitors in cancer research and therapy

  2011cited by this paper
• Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

  2011cited by this paper
• Expression of BDNF, TrkB, and p53 in early-stage squamous cell carcinoma of the uterine cervix

  2011cited by this paper
• The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.

  2011cited by this paper
• A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors.

  2011cited by this paper
• MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

  2011cited by this paper
• Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis.

  2011cited by this paper
• Resistance of colorectal cancer cells to radiation and 5-FU is associated with MELK expression.

  2011cited by this paper
• HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy

  2010cited by this paper
• Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

  2010cited by this paper
• Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer.

  2010cited by this paper
• A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

  2010cited by this paper
• American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development.

  2010cited by this paper
• Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer

  2010cited by this paper
• The SYK tyrosine kinase: a crucial player in diverse biological functions

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• Roles of GSK3 in metabolic shift toward abnormal anabolism in cell senescence

  2010cited by this paper

• A homogeneous mass-encoded strategy for mass spectrometric biosensing of multiplex proteins.

  2025cites this paper
• Cellular and Molecular Mechanisms of Oxidative DNA Damage and Repair

  2025cites this paper
• Digital Twin-Based Multiscale Models for Biomarker Discovery in Kinase and Phosphatase Tumorigenic Processes

  2025cites this paper
• Electrochemical assay for the quantification of anticancer drugs and their inhibition mechanism.

  2025cites this paper
• Clinical and gonadal transcriptome analysis of 38,XX disorder of sex development pigs

  2024cites this paper
• Identification of a novel immune checkpoint-related gene signature predicts prognosis and immunotherapy in breast cancer and experiment verification

  2024cites this paper
• Framework Nucleic Acid-Based Multifunctional Tumor Theranostic Nanosystem for miRNA Fluorescence Imaging and Chemo/Gene Therapy.

  2023cites this paper
• Peptide‐Based Inhibitors that Target the Docking Site of ERK2

  2022cites this paper
• mTOR as a Potential Target for the Treatment of Microbial Infections, Inflammatory Bowel Diseases, and Colorectal Cancer

  2022cites this paper
• MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway

  2021cites this paper
• Fyn Kinase-Mediated PKCδ Y311 Phosphorylation Induces Dopaminergic Degeneration in Cell Culture and Animal Models: Implications for the Identification of a New Pharmacological Target for Parkinson’s Disease

  2021cites this paper
• MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway.

  2021cites this paper
• Combination of multifunctional ursolic acid with kinase inhibitors for anti-cancer drug carrier vesicles.

  2021cites this paper
• Uncovering Tumour Heterogeneity through PKR and nc886 Analysis in Metastatic Colon Cancer Patients Treated with 5-FU-Based Chemotherapy

  2020cites this paper
• Significance of BRAF and Nrf2 in evaluation of serous ovarian tumors

  2020cites this paper
• CircASPH promotes KGN cells proliferation through miR‐375/MAP2K6 axis in Polycystic Ovary Syndrome

  2020cites this paper
• Bioinformatics analysis combined with experiments to explore potential prognostic factors for pancreatic cancer

  2020cites this paper
• Discovery of new potential CDK2/VEGFR2 type II inhibitors by fragmentation and virtual screening of natural products

  2020cites this paper
• Studies on Structures and Functions of Kinases leading to Prostate Cancer and Their Inhibitors

  2020cites this paper
• Kinobead/LC-MS Phosphokinome Profiling Enables Rapid Analyses of Kinase-Dependent Cell Signaling Networks.

  2019cites this paper
• Myricetin inhibits panel of kinases implicated in tumorigenesis

  2019cites this paper
• Dissection of Protein Kinase Pathways in Live Cells Using Photoluminescent Probes: Surveillance or Interrogation?

  2018cites this paper
• MAP2K6 is associated with radiation resistance and adverse prognosis for locally advanced nasopharyngeal carcinoma patients

  2018cites this paper
• Targeting Oxidatively Induced DNA Damage Response in Cancer: Opportunities for Novel Cancer Therapies

  2018cites this paper
• Methods and approaches to disease mechanisms using systems kinomics

  2017cites this paper
• Editorial: Recent Advances in the Field of Kinases and Kinase Inhibitors.

  2017cites this paper